Clinical Trials · us
RAP-219 Phase 2 Trial Shows Improvement in Mania, but Discontinuation Rates Remain a Challenge Beyond Three-Week Efficacy
A 253-person trial shows that RAP-219 can reduce acute mania in bipolar disorder, but a higher proportion of patients in the treatment group ended treatment early. Whether the efficacy of this new mechanism can be consistently replicated, and whether tolerability is sufficient to support continued treatment, will be key questions for Phase 3 trials.
Acute mania can disrupt sleep, thoughts, and behavior together, and treatment must both calm symptoms and be acceptable enough for patients to continue. Rapport Therapeutics announced on October 20 that its investigational drug RAP-219 produced greater improvement in mania scores than placebo after three weeks in a Phase 2 study, providing preliminary human evidence for a new treatment mechanism. However, the higher treatment discontinuation rate in the drug group also leaves questions that need clarification.
The randomized, double-blind, placebo-controlled trial, conducted in the United States, enrolled 253 adults with bipolar I disorder who were experiencing an acute manic episode. Of these, 126 received RAP-219 and 127 received placebo. Patients were treated in an inpatient setting for three weeks; after dose titration over two or four days, RAP-219 was administered at 0.75 mg daily, with efficacy analyzed across the two titration regimens combined. Existing bipolar disorder medications, anti-anxiety medications, and sleep medications were discontinued during screening, but the trial permitted lorazepam as rescue medication under specified conditions.
The primary efficacy endpoint was the change in the Young Mania Rating Scale (YMRS), with lower scores indicating reduced symptoms. At week three, the statistically modeled mean reduction was 15.4 points in the RAP-219 group and 12.3 points in the placebo group, a between-group difference of 3.1 points that reached statistical significance (p = 0.045). A report published the same day by *Psychiatric Times* listed the same results. This supports a signal of drug efficacy, but statistical significance alone does not establish how much patients’ daily functioning improved, nor does it demonstrate superiority over existing treatments.
RAP-219 targets excitatory signaling in the brain. According to the company’s presentation, it selectively modulates the activity of AMPA receptors associated with the auxiliary protein TARPγ8, with the aim of reducing excitatory glutamate signaling in specific neural circuits. This design offers a different research direction for treating mania, but the current short-term trial cannot yet establish whether it can prevent relapse or which patients might be suited to long-term use.
Interpretation of efficacy must also account for patients who did not complete treatment. The company’s presentation showed that 95 patients in the RAP-219 group completed the three-week course, compared with 112 in the placebo group. Overall treatment discontinuation rates were 24.6% and 11.8%, respectively, with withdrawal of consent accounting for 16.7% and 4.7%. The analysis retained data collected before discontinuation and handled subsequent missing data under a “missing at random” assumption, meaning that missingness was assumed to be explainable by observed data. The different withdrawal rates between the groups make the results’ dependence on this assumption a key point for assessment; withdrawal of consent also cannot be attributed entirely to drug side effects.
Regarding safety, treatment-emergent adverse events occurred within the three weeks in 51.6% of the RAP-219 group and 52.8% of the placebo group. All reported events were mild or moderate, and no serious adverse events were observed. However, agitation occurred in 16.7% versus 9.4%, and nausea in 5.6% versus 1.6%; discontinuation due to adverse events occurred in 3.2% versus 0.8%. These figures describe events occurring during treatment and do not mean that every event was caused by the drug, nor are they sufficient to rule out less common or later-emerging risks.
The results released so far are preliminary summary findings, and safety follow-up data from the eight weeks after treatment discontinuation have yet to be published. Rapport plans to discuss subsequent trial design with the U.S. Food and Drug Administration in the first quarter of 2027 and expects to initiate two Phase 3 trials in the second half of the same year. Further validation will need to confirm whether the three-week difference in scores can be replicated, provide a clearer account of why patients withdrew, and establish whether short-term tolerability can translate into an advantage for continued treatment.